Q3 2023 Results slide image

Q3 2023 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Conclusions Financial performance Immunology Neuroscience Ophthalmology Ophthalmology Appendix Innovation: Clinical trials Oncology Global Health References Abbreviations Other 78 Investor Relations | Q3 2023 Results 1 NOVARTIS | Reimagining Medicine
View entire presentation